

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): September 19, 2022**

**CATALYST PHARMACEUTICALS, INC.**  
(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33057**  
(Commission  
File Number)

**76-0837053**  
(I.R.S. Employer  
Identification No.)

**355 Alhambra Circle  
Suite 801  
Coral Gables, Florida**  
(Address of principal executive offices)

**33134**  
(Zip Code)

**Registrant's telephone number, including area code: (305) 420-3200**

**Not Applicable**  
**Former Name or Former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Exchange on Which Registered	Ticker Symbol
<b>Common Stock, par value \$0.001 per share</b>	<b>NASDAQ Capital Market</b>	<b>CPRX</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

At the Company's 2022 Annual Meeting of Stockholders held on September 19, 2022, Patrick J. McEnany, Philip H. Coelho, Charles B. O'Keeffe, David S. Tierney, Donald A. Denkhaus, Richard J. Daly and Molly Harper were elected to the Company's Board of Directors to serve until the 2023 Annual Meeting of Stockholders or until their successor is duly elected and qualified, or until their earlier death, resignation or removal.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On September 19, 2022, the Company held its 2022 Annual Meeting of Stockholders. The final voting results on the matters considered at the meeting were as follows:

1. Election of Directors:

Name	Votes For	Votes Against	Votes Abstained	Broker Non-Votes
Patrick J. McEnany	67,776,079	892,300	83,337	10,412,781
Philip H. Coelho	46,207,371	22,293,715	250,630	10,412,781
Charles B. O'Keeffe	64,025,823	4,649,736	76,157	10,412,781
David S. Tierney	64,738,321	3,941,791	71,604	10,412,781
Donald A. Denkhaus	63,954,807	4,722,693	74,216	10,412,781
Richard J. Daly	65,208,375	3,465,408	77,933	10,412,781
Molly Harper	65,556,875	3,132,740	62,101	10,412,781

2. Approval, on an advisory basis, of 2021 compensation of our named executive officers

Votes For	Votes Against	Votes Abstained	Broker Non-Votes
66,515,582	2,124,782	111,352	10,412,781

3. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022:

Votes For	Votes Against	Votes Abstained
77,752,748	1,365,402	46,347

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceuticals, Inc.**

By: \_\_\_\_\_ /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: September 19, 2022